The antibody is being assessed in the Phase IIa CBeyond trial for obesity. Credit: nito/Shutterstock. Skye Bioscience has partnered with Arecor Therapeutics to develop a higher formulation of the former’s obesity candidate nimacimab, a cannabinoid receptor 1 (CB1)-inhibiting monoclonal antibody. The […]
Skye and Arecor to develop higher formulation of CB1 inhibitor Read More »
GSK’s Blenrep combos are undergoing review in worldwide markets. Credit: HJBC/Shutterstock. The Japanese Ministry of Health, Labour and Welfare (MHLW) has granted approval for the use of GSK’s Blenrep (belantamab mafodotin) combinations to treat adults with relapsed or refractory multiple
Japan’s MHLW approves GSK’s Blenrep combos for MM Read More »
Pfizer will invest $100m in 3SBio, in accordance with a securities subscription agreement between the two entities. Credit: Jonathan Weiss/Shutterstock. Pfizer has signed a worldwide licensing agreement, excluding China, with biopharmaceutical company 3SBio to develop, manufacture and commercialise bispecific antibody
Pfizer signs global licensing deal with 3SBio for bispecific antibody Read More »
Incyte markets the antibody in the US. Credit: JHVEPhoto/Shutterstock. The US Food and Drug Administration (FDA) has approved Incyte’s humanised monoclonal antibody Zynyz (retifanlimab-dlwr) in conjunction with carboplatin and paclitaxel (platinum-based chemo) for the first-line treatment of adults with inoperable
FDA approves Incyte’s retifanlimab combo for SCAC treatment Read More »
BMS’ Opdivo-based options have secured approvals for various types of tumours in the EU. Credit: Felix Geringswald/Shutterstock. The European Commission (EC) has granted approval to Bristol Myers Squibb’s (BMS) perioperative regimen of neoadjuvant Opdivo (nivolumab), combined with chemotherapy and followed by
EC approves BMS’ perioperative Opdivo and chemo for NSCLC Read More »
BioMarin will commence a cash tender offer to purchase all outstanding shares of Inozyme common stock. Credit: T. Schneider/Shutterstock. BioMarin Pharmaceutical has agreed to acquire Inozyme Pharma for $4.00 per share in a $270m all-cash transaction. This will enhance BioMarin’s
BioMarin agrees to acquire Inozyme for $270m Read More »
Amneal’s autoinjector allows patients to administer their dose subcutaneously into the middle part of the thigh. Credit: MacroEcon/Shutterstock. The US Food and Drug Administration (FDA) has approved Amneal Pharmaceuticals’ Brekiya (dihydroergotamine (DHE) mesylate) autoinjector for the treatment of acute migraine with
FDA approves Amneal’s DHE autoinjector for migraine Read More »
AGC Biologics provides services for viral vector-based therapies. Credit: © 2025 AGC Biologics. All Rights Reserved. AGC Biologics has collaborated with biotechnology company Quell Therapeutics to advance the development of several T-regulatory (Treg) cell therapy drug candidates to treat severe
AGC Biologics and Quell to progress Treg cell therapy development Read More »
Pathos is focused on expediting innovation in oncology through a new model for drug development. Credit: Cast Of Thousands/Shutterstock. Pathos AI has raised $365m in a Series D funding round as it prepares to widen its AI-enabled platform to advance
Pathos AI raises $365m for oncology drug development Read More »
BioCryst plans additional regulatory filings for the therapy in other worldwide territories, including Canada and Japan. Credit: MacroEcon/Shutterstock. The US Food and Drug Administration (FDA) has accepted BioCryst Pharmaceuticals’ new drug application (NDA) for Orladeyo (berotralstat), granting it priority review
FDA awards BioCryst’s Orladeyo NDA for paediatric HAE Read More »
